BusinessBiogen’s Alzheimer’s Drug Is a Wall Street Winner, Controversy...

Biogen’s Alzheimer’s Drug Is a Wall Street Winner, Controversy or Not

-


Biogen’s


BIIB 38.34%

Alzheimer’s treatment has reached the market. And all of a sudden, a plodding value stock has a compelling growth story.

U.S. regulators gave the green light to the drug known as aducanumab, the first such approval of any drug that promises to slow the progression of the fatal disease. Millions of patients world-wide potentially stand to benefit.

Accordingly, Wall Street thinks Biogen has a blockbuster on its hands. While the company has said to expect a slow rollout at first, analysts estimate about $10 billion in annual sales later this decade at its peak. Biogen shares surged 38% on Monday, and a broad biotech index gained nearly 5% on the day.

For Biogen, that prospective growth is badly needed: The company expects to book roughly $10.6 billion in total revenue this year. Sales of its top-selling multiple sclerosis drug Tecfidera are falling as generic competition comes online in the U.S.

There are reasons to be skeptical that aducanumab can ever meet analysts’ lofty expectations. For starters, patients will require testing before receiving the drug that can result in hefty out-of-pocket costs for patients insured by Medicare.

It is possible that the controversy surrounding the drug’s approval will hinder sales. An outside panel of experts assembled by the U.S. Food and Drug Administration voted overwhelmingly not to support approval last year for lack of efficacy. Some prescribing physicians may agree.

And even if those concerns don’t end up limiting demand, Biogen might not enjoy market exclusivity for as long as Wall Street thinks. Rival drugmakers have mothballed similar treatments over the years and could now choose to revive them, given the FDA’s evident flexibility. And the drug’s list price of $56,000 a year is bound to raise eyebrows in Washington, D.C.

Those concerns won’t likely matter to Wall Street any time soon, however. Biogen was trading at less than 12 times last year’s earnings on Monday before the news broke.

Monday’s rally still leaves Biogen at 16 times earnings, according to generally accepted accounting principles. That hardly seems unreasonable. After all, the stock traded as high as 25 times earnings back in 2015, when aducanumab showed promising results in early trials.

Besides, in today’s frothy stock market, investors often find tales of a bright future far more appealing than real cash being generated in the present. Biogen now has a better story to tell.

Write to Charley Grant at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the June 8, 2021, print edition as ‘Investors Like Biogen for Alzheimer’s.’

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Chris Hogan Left Lacrosse. A League Has Given Him, and Others, a Path Back.

In high school, Chris Hogan didn’t see a path forward in lacrosse.He played three years at Penn State,...

How to Watch the Westminster Dog Show

When and where is the Westminster dog show?The Westminster Kennel Club Dog Show this year is in a...

Yankees Rally to Tie Before Losing in Extra Innings

PHILADELPHIA — Jean Segura scored Ronald Torreyes with an infield single in the 10th inning for his second...

FDA Details Failures at Baltimore Plant That Spoiled Vaccine Doses

A Baltimore factory that rendered useless 75 million doses of a coronavirus vaccine developed by Johnson & Johnson...

French Open Champion Krejcikova Thanks Her Mentor, Novotna

There were rare moments of agitation, including one shout to her player box during Saturday’s final, but Stubbs...

Denmark’s Christian Eriksen collapsed on the field. He is responsive and awake.

Denmark midfielder Christian Eriksen collapsed to the field late in the first half of his team’s game against...

Venezuela Faces Coronavirus Outbreak Ahead of Copa América Tournament

At least a dozen Venezuela players and staff members have tested positive for the coronavirus a day before...

Must read

Chris Hogan Left Lacrosse. A League Has Given Him, and Others, a Path Back.

In high school, Chris Hogan didn’t see a...

How to Watch the Westminster Dog Show

When and where is the Westminster dog show?The...

Yankees Rally to Tie Before Losing in Extra Innings

PHILADELPHIA — Jean Segura scored Ronald Torreyes with...

FDA Details Failures at Baltimore Plant That Spoiled Vaccine Doses

A Baltimore factory that rendered useless 75 million...

French Open Champion Krejcikova Thanks Her Mentor, Novotna

There were rare moments of agitation, including one...

You might also likeRELATED
Recommended to you